Suppr超能文献

停用SGLT2抑制剂后出现正常血糖性糖尿病酮症酸中毒

Euglycemic Diabetic Ketoacidosis after Discontinuing SGLT2 Inhibitor.

作者信息

Alhemeiri Mohamed, Alseddeeqi Eiman

机构信息

Medical Education Department, Sheikh Khalifa Medical City, P.O. Box 51900, Abu Dhabi, UAE.

Division of Endocrinology, Sheikh Khalifa Medical City, P.O. Box51900, Abu Dhabi, UAE.

出版信息

Case Rep Endocrinol. 2022 Mar 2;2022:4101975. doi: 10.1155/2022/4101975. eCollection 2022.

Abstract

BACKGROUND

Sodium glucose cotransporter-2 (SGLT2) inhibitors have been proven to be very effective in the management of type II diabetes. These medications can cause adverse drug reactions such as genital mycotic infections. Another critical adverse drug reaction is euglycemic diabetic ketoacidosis (EDKA) under the setting of other contributing risk factors for developing diabetic ketoacidosis. . We report a case of a 45-year-old gentleman with type 2 diabetes mellitus on empagliflozin, metformin, and glimepiride who presented with abdominal pain, fatigue, and vomiting. Of note, he started a ketogenic diet three days before his presentation and self-stopped his antidiabetic medications two days before his presentation. The patient was found to have euglycemic diabetic ketoacidosis and was treated as per the protocol. He was discharged on metformin and pioglitazone. Two weeks following discharge, canagliflozin was added.

CONCLUSION

Euglycemic diabetic ketoacidosis could still be precipitated despite discontinuation of SGLT2I under a ketogenic diet. Discussion related to the initiation of a ketogenic diet should occur between the care provider and the patient.

摘要

背景

钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂已被证明在2型糖尿病的管理中非常有效。这些药物可引起不良药物反应,如生殖器霉菌感染。另一个关键的不良药物反应是在存在其他导致糖尿病酮症酸中毒的危险因素的情况下发生的正常血糖性糖尿病酮症酸中毒(EDKA)。我们报告一例45岁2型糖尿病男性患者,正在服用恩格列净、二甲双胍和格列美脲,出现腹痛、乏力和呕吐。值得注意的是,他在就诊前三天开始生酮饮食,并在就诊前两天自行停用了抗糖尿病药物。该患者被诊断为正常血糖性糖尿病酮症酸中毒,并按照方案进行治疗。他出院时服用二甲双胍和吡格列酮。出院两周后,加用了卡格列净。

结论

尽管在生酮饮食下停用了SGLT2抑制剂,但仍可能诱发正常血糖性糖尿病酮症酸中毒。医疗服务提供者和患者之间应就生酮饮食的启动进行讨论。

相似文献

1
Euglycemic Diabetic Ketoacidosis after Discontinuing SGLT2 Inhibitor.
Case Rep Endocrinol. 2022 Mar 2;2022:4101975. doi: 10.1155/2022/4101975. eCollection 2022.
4
Can euglycemic Diabetic Ketoacidosis Caused by SGLT2 Inhibitors be avoided in Covid-19 and other acute Infections?
Eur J Case Rep Intern Med. 2024 Feb 2;11(3):004282. doi: 10.12890/2024_004282. eCollection 2024.
5
8
Euglycemic diabetic ketoacidosis caused by dapagliflozin: A case report.
Medicine (Baltimore). 2018 Jun;97(25):e11056. doi: 10.1097/MD.0000000000011056.
9
Euglycemic Diabetic Ketoacidosis Due to SGLT2 Inhibitor in a Patient With Gitelman Syndrome: A Therapeutic Dilemma.
Cureus. 2021 Oct 31;13(10):e19169. doi: 10.7759/cureus.19169. eCollection 2021 Oct.

引用本文的文献

1
Developing a Protocol for Management of Euglycemic Diabetic Ketoacidosis.
Curr Diab Rep. 2025 Sep 3;25(1):48. doi: 10.1007/s11892-025-01604-3.
2
SGLT2 Inhibitors: From Structure-Effect Relationship to Pharmacological Response.
Int J Mol Sci. 2025 Jul 19;26(14):6937. doi: 10.3390/ijms26146937.
3
Progress in the treatment of diabetic cardiomyopathy, a systematic review.
Pharmacol Res Perspect. 2024 Apr;12(2):e1177. doi: 10.1002/prp2.1177.
5
Challenges in hyperglycemia management in critically ill patients with COVID-19.
World J Crit Care Med. 2022 Jul 9;11(4):219-227. doi: 10.5492/wjccm.v11.i4.219.
6
Euglycaemic diabetic ketoacidosis in a patient with pancreatitis and type 2 diabetes on empagliflozin.
BMJ Case Rep. 2022 Jun 22;15(6):e247921. doi: 10.1136/bcr-2021-247921.

本文引用的文献

2
A Case of Diabetic Ketoacidosis in a Patient on an SGLT2 Inhibitor and a Ketogenic Diet: A Critical Trio Not to Be Missed.
Case Rep Endocrinol. 2020 Aug 13;2020:8832833. doi: 10.1155/2020/8832833. eCollection 2020.
3
SGLT2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis: A Case Report.
Kidney Med. 2020 Feb 22;2(2):218-221. doi: 10.1016/j.xkme.2019.12.006. eCollection 2020 Mar-Apr.
7
A Case Report: Euglycemic Diabetic Ketoacidosis Presenting as Chest Pain in a Patient on a Low Carbohydrate Diet.
Curr Diabetes Rev. 2021;17(2):243-246. doi: 10.2174/1573399816666200316112709.
8
Euglycemic diabetic ketoacidosis caused by canagliflozin: a case report.
Int J Emerg Med. 2020 Jan 22;13(1):2. doi: 10.1186/s12245-020-0261-8.
10
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician's Guide.
Diabetes Metab Syndr Obes. 2019 Oct 14;12:2125-2136. doi: 10.2147/DMSO.S212003. eCollection 2019.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验